Degarelix, a novel GnRH blocker from Ferring, moves into phase III (in English)

Degarelix, a novel GnRH blocker from Ferring, moves intsustained reductions in testosterone and prostate-specific antigen (PSA) levels without a testosterone surge.

The results of the Phase IIb programme with Degarelix in prostate cancer, which are in line with previous promising studies, Ferring Pharmaceuticals announced the immediate start of Phase III trials.

The findings from the international multi-centre trial in 187 men showed that 100% of those treated with an initial dose of 240 mg and a maintenance dose of 160 mg achieved androgen deprivation from day 28 to the full year. Androgen deprivation achieves disease control in prostate cancer patients.

Source: Press release from Ferring Pharmaceuticals, 07.04.06.

Read more at the Ferring homepage